0001104659-19-062782.txt : 20191112 0001104659-19-062782.hdr.sgml : 20191112 20191112190241 ACCESSION NUMBER: 0001104659-19-062782 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191108 FILED AS OF DATE: 20191112 DATE AS OF CHANGE: 20191112 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bitterman Kevin CENTRAL INDEX KEY: 0001591747 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38944 FILM NUMBER: 191211325 MAIL ADDRESS: STREET 1: C/O POLARIS VENTURE PARTNERS STREET 2: 1000 WINTER STREET, SUITE 3350 CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Akero Therapeutics, Inc. CENTRAL INDEX KEY: 0001744659 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 170 HARBOR WAY CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-487-6488 MAIL ADDRESS: STREET 1: 170 HARBOR WAY CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 a4.xml 4 X0306 4 2019-11-08 0 0001744659 Akero Therapeutics, Inc. AKRO 0001591747 Bitterman Kevin C/O AKERO THERAPEUTICS, INC. 170 HARBOR WAY, 3RD FLOOR SOUTH SAN FRANCISCO CA 94080 1 0 0 0 Stock Option (Right to Buy) 19.97 2019-11-08 4 A 0 26000 0 A 2029-11-07 Common Stock 26000 26000 D This option shall vest and become exercisable in 36 equal monthly installments, commencing on November 8, 2019. This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC, and as such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. /s/ Kevin Bitterman 2019-11-12